Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate - PubMed (original) (raw)
Comparative Study
. 2006 Mar 31;281(13):8582-90.
doi: 10.1074/jbc.M509043200. Epub 2006 Feb 2.
Affiliations
- PMID: 16455650
- DOI: 10.1074/jbc.M509043200
Free article
Comparative Study
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
Alexei F Kisselev et al. J Biol Chem. 2006.
Free article
Abstract
The relative importance of the different proteolytic sites in mammalian proteasomes in protein degradation has not been studied systematically. Nevertheless, it is widely assumed that inhibition of the chymotrypsin-like site, the primary target of the proteasome inhibitors used in research and cancer therapy, reflects the degree of inhibition of protein breakdown. Here we demonstrate that selective inactivation of the chymotrypsin-like site reduced degradation of model proteins by pure 26 S proteasomes by only 11-50% and decreased only slightly the breakdown of proteins in HeLa cells. Inactivation of the caspase-like site decreased breakdown of model proteins by 12-22% and of the trypsin-like site by 3-35%. The relative contributions of these different sites depended on the protein substrate, and the importance of the trypsin-like sites depended on the substrate's content of basic residues. Simultaneous inhibition of the chymotrypsin-like and the caspase- or trypsin-like sites was needed to reduce degradation by >50%. Thus, 1) all three types of active sites contribute significantly to protein breakdown, 2) their relative importance varies widely with the substrate, 3) assaying the chymotrypsin-like activity overestimates the actual reduction in protein degradation, and 4) inhibition of multiple sites is required to markedly decrease proteolysis.
Similar articles
- The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.
Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, Thornberry NA, Goldberg AL. Kisselev AF, et al. J Biol Chem. 2003 Sep 19;278(38):35869-77. doi: 10.1074/jbc.M303725200. Epub 2003 Jun 18. J Biol Chem. 2003. PMID: 12815064 - Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates.
Kisselev AF, Goldberg AL. Kisselev AF, et al. Methods Enzymol. 2005;398:364-78. doi: 10.1016/S0076-6879(05)98030-0. Methods Enzymol. 2005. PMID: 16275343 - Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.
Britton M, Lucas MM, Downey SL, Screen M, Pletnev AA, Verdoes M, Tokhunts RA, Amir O, Goddard AL, Pelphrey PM, Wright DL, Overkleeft HS, Kisselev AF. Britton M, et al. Chem Biol. 2009 Dec 24;16(12):1278-89. doi: 10.1016/j.chembiol.2009.11.015. Chem Biol. 2009. PMID: 20064438 Free PMC article. - [Proteasome inhibitors in cancer therapy].
Romaniuk W, Ołdziej AE, Zińczuk J, Kłoczko J. Romaniuk W, et al. Postepy Hig Med Dosw (Online). 2015 Dec 31;69:1443-50. Postepy Hig Med Dosw (Online). 2015. PMID: 27259216 Review. Polish. - Homogeneous, bioluminescent proteasome assays.
O'Brien MA, Moravec RA, Riss TL, Bulleit RF. O'Brien MA, et al. Methods Mol Biol. 2008;414:163-81. doi: 10.1007/978-1-59745-339-4_13. Methods Mol Biol. 2008. PMID: 18175819 Review.
Cited by
- HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
Besse A, Sedlarikova L, Buechler L, Kraus M, Yang CH, Strakova N, Soucek K, Navratil J, Svoboda M, Welm AL, Joerger M, Driessen C, Besse L. Besse A, et al. Br J Cancer. 2024 Sep;131(5):918-930. doi: 10.1038/s41416-024-02774-9. Epub 2024 Jul 5. Br J Cancer. 2024. PMID: 38969867 Free PMC article. - Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.
Murzyn A, Orzeł J, Obajtek N, Mróz A, Miodowska D, Bojdo P, Gąsiorkiewicz B, Koczurkiewicz-Adamczyk P, Piska K, Pękala E. Murzyn A, et al. Cancer Chemother Pharmacol. 2024 Aug;94(2):123-139. doi: 10.1007/s00280-024-04693-1. Epub 2024 Jul 4. Cancer Chemother Pharmacol. 2024. PMID: 38965080 Free PMC article. Review. - Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome.
Fernandes PMP, Guedes RA, Victor BL, Salvador JAR, Guedes RC. Fernandes PMP, et al. Front Chem. 2024 Jan 8;11:1322628. doi: 10.3389/fchem.2023.1322628. eCollection 2023. Front Chem. 2024. PMID: 38260042 Free PMC article. - A Lysine Residue at the C-Terminus of MHC Class I Ligands Correlates with Low C-Terminal Proteasomal Cleavage Probability.
Schmalen A, Kammerl IE, Meiners S, Noessner E, Deeg CA, Hauck SM. Schmalen A, et al. Biomolecules. 2023 Aug 24;13(9):1300. doi: 10.3390/biom13091300. Biomolecules. 2023. PMID: 37759700 Free PMC article. - Blunting Neuroinflammation by Targeting the Immunoproteasome with Novel Amide Derivatives.
Imbesi C, Ettari R, Irrera N, Zappalà M, Pallio G, Bitto A, Mannino F. Imbesi C, et al. Int J Mol Sci. 2023 Jun 27;24(13):10732. doi: 10.3390/ijms241310732. Int J Mol Sci. 2023. PMID: 37445907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources